Hepatitis B
High HBV Viral Load Linked to Greater Risk of Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 17 January 2012 00:00
- Written by Liz Highleyman
Having a high blood level of hepatitis B virus (HBV) DNA increases the likelihood of developing hepatocellular carcinoma (HCC), a form of primary liver cancer, according to a study described in the January 13, 2012, Journal of Virology.
Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 10 January 2012 00:00
- Written by Press Release
Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major cause of hepatocellular carcinoma (HCC, a form of primary liver cancer) in the U.S., according to a study by researchers at the Mayo Clinic in Rochester, MN. A related analysis found that among immigrants from Somalia, hepatitis B and C were both significant causes of liver cancer.
More U.S. Immigrants May Have Hepatitis B than Previously Estimated
- Details
- Category: HBV Epidemiology & Mortality
- Published on Tuesday, 06 December 2011 00:00
- Written by Liz Highleyman
The number of foreign-born individuals with chronic hepatitis B virus (HBV) infection in the U.S. may be considerably higher than earlier estimates suggest, according to a study described in the November 22, 2011, advance online edition of Hepatology.
MicroRNA Blood Test May Help Diagnose Early Liver Cancer in People with Hepatitis B
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
- Written by Liz Highleyman
A set of 7 microRNAs in blood plasma accurately diagnosed hepatocellular carcinoma (HCC) and could distinguish between liver cancer and cirrhosis among people with chronic hepatitis B, according to study findings reported in the November 21, 2011, advance online edition of the Journal of Clinical Oncology.
AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Doubling the usual dose of entecavir (Baraclude) did not increase its effectiveness for treating chronic hepatitis B, according to a study presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) this month in San Francisco.
Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 27 December 2011 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for the nucleoside analog telbivudine (Tyzeka), indicating that it should not be used with pegyalted interferon alfa-2a (brand name Pegasys) for the treatment of hepatitis B because the combination can cause peripheral neuropathy, or nerve damage.
AASLD 2011: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression
- Details
- Category: HBV Treatment
- Published on Tuesday, 22 November 2011 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who achieve HBV DNA viral load suppression on entecavir (Baraclude) have a lower risk of liver failure, hepatocellular carcinoma, and death than non-responders, according to study findings presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: Natural History of Hepatitis B Infection and Role of HBV Genotype
- Details
- Category: Hepatitis B
- Published on Tuesday, 20 December 2011 00:00
- Written by Liz Highleyman
People with hepatitis B "e" antigen (HBeAg) positive and negative disease have different levels of hepatitis B surface antigen (HBsAg), variable extent of liver fibrosis, and different distribution of HBV genotypes, according to a study presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting last month in San Francisco.
AASLD 2011: Long-term Tenofovir for HIV/HBV Coinfection
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Tenofovir showed long-term antiviral activity against hepatitis B virus (HBV) lasting 5 to 8 years, with minimal evidence of kidney toxicity, and HBsAg levels declined steadily over time, according to 2 posters presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
More Articles...
- AASLD 2011: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer
- AASLD 2011: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis
- Some People with Hepatitis B May Need Liver Cancer Screening Sooner and More Often
- CDC Advisory Committee Recommends Hepatitis B Vaccine for People with Diabetes
- Gilead and GlobeImmune Will Collaborate on Hepatitis B Therapeutic Vaccine
Web Design and Development by